Inhibition of prothrombinase at macroscopic lipid membranes:Competition between antithrombin and prothrombin by Billy, Didier et al.
 
 
 
Inhibition of prothrombinase at macroscopic lipid
membranes
Citation for published version (APA):
Billy, D., Speijer, H., Lindhout, T., Hemker, H. C., & Willems, G. M. (1995). Inhibition of prothrombinase at
macroscopic lipid membranes: Competition between antithrombin and prothrombin. Biochemistry, 34(41),
13699-13704. https://doi.org/10.1021/bi00041a052
Document status and date:
Published: 17/10/1995
DOI:
10.1021/bi00041a052
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Jan. 2021
Biochemistry 1995,34, 13699- 13704 13699 
Inhibition of Prothrombinase at Macroscopic Lipid Membranes: Competition 
between Antithrombin and Prothrombin 
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ABSTRACT: The kinetics of inhibition of prothrombinase during prothrombin conversion by antithrombin 
and antithrombin-heparin complexes was studied in a tubular flow reactor. Prothrombinase was assembled 
at a macroscopic phospholipid membrane, composed of 25 mol % phosphatidylserine and 75 mol % 
phosphatidylcholine, deposited on the inner wall of a glass capillary, by perfusion with a factor Xa- 
factor Va mixture. Measurement of thrombin production allowed estimation of the amount of 
prothrombinase present at the capillary wall. Perfusion with a mixture of prothrombin and antithrombin 
or antithrombin-heparin complexes caused a progressive decline of the prothrombinase activity. The 
rate of inactivation steeply decreased with increasing prothrombin concentrations, indicating competitive 
inhibition. Analysis of competitive inhibition data requires estimation of the time-dependent substrate 
concentration, C,, near the prothrombin converting surface using earlier developed transport theory [Billy, 
D., et al. (1995) J .  Biol. Chem. 270, 1029-10341. It appears that the inhibition rate is proportional to the 
fraction of enzyme, K,/(Km -I- C,), not occupied by substrate. The value of K, of prothrombinase estimated 
from the dependence of the inhibition rate on the prothrombin concentration (K ,  = 2-3 nM) is in excellent 
agreement with the value estimated from the substrate conversion rate (K ,  = 3 nM). Therefore inhibition 
of prothrombinase by antithrombin and antithrombin-heparin complexes is fully competitive with the 
substrate: prothrombin. Our results show that prothrombinase assembled on macroscopic lipid surfaces 
by virtue of its low K,  value is protected for inhibition due to highly effective competition of prothrombin 
with antithrombin for the active site of factor Xa. 
The activation of prothrombin to thrombin is a central 
reaction of the blood coagulation that finally results in the 
formation of a hemostatic plug (Jackson & Nemerson, 1980; 
Mann et al., 1990). Effective activation of prothrombin 
requires prothrombinase, the complex of the serine protease 
factor Xa and cofactor Va assembled on a phosphati- 
dylserine-containing phospholipid membrane (Hemker et al., 
1967; Nesheim et al., 1979; Rosing et al., 1980). The spatial 
propagation of the coagulation activation reactions is re- 
stricted by the requirement of phosphatidylserine-containing 
membranes, in vivo presumably provided by activated 
platelets and vascular lesions (Rosing et al., 1985; Mann et 
al., 1990; Zwaal et al., 1992, Comfurius et al., 1994). 
Furthermore, the coagulation is down-regulated in time by 
several inactivation reactions. The cofactors Va and VIIIa 
are eliminated by activated protein C (Esmon, 1989) that 
becomes available during thrombin generation. The extrinsic 
pathway is inhibited by tissue factor pathway inhibitor 
(Rapaport, 1989). The serine proteases of the blood coagu- 
lation are primarily inhibited by antithrombin (Egeberg, 1965; 
Abilgaard, 1969). This protein, with a plasma concentration 
of about 2 pM, forms equimolar complexes with serine 
proteases. The principal targets of antithrombin are factor 
Xa and thrombin. Heparin, widely in use as anticoagulant 
drug, up to 1000-fold enhances the rate of inactivation of 
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these enzymes by antithrombin (Rosenberg & Damus, 1973; 
Danielsson et al., 1986; Olson, 1988; Craig et al., 1989). 
Kinetics of prothrombin conversion by prothrombinase 
bound to macroscopic phospholipid surfaces has recently 
been studied in our laboratory both on uniformly accessible 
surfaces, Le., the rotating disc, and in the tubular flow reactor 
(Schoen et al., 1990; Giesen et al., 1991; Willems et al., 1993; 
Billy et al., 1995). It was shown that analysis of kinetics 
requires a careful account of mass transfer to the catalytic 
surface. The most important observation was the huge 
catalytic efficiency of prothrombinase bound to planar 
bilayers because of the extremely low value of the Michaelis 
constant ( K ,  = 3 nM), which is nearly two orders lower 
than found for prothrombinase bound to small vesicles 
(Rosing et al., 1980; Giesen et al., 1991). This could imply 
that inhibition of prothrombinase bound to macroscopic lipid 
membranes by pseudo-substrates like antithrombin can be 
easily counteracted by the presence of prothrombin. Indeed 
a recent study demonstrated a nearly complete protection 
from antithrombin-mediated inhibition by prothrombin (Speijer 
et al., 1995). 
This paper reports a detailed kinetic study on the competi- 
tive effect of prothrombin on the inactivation of prothrom- 
binase by antithrombin. Our main goal was elucidate to what 
extent the protection of prothrombinase could be attributed 
to competition between prothrombin and antithrombin for 
the active site of factor Xa. By restriction of our measure- 
ments to low densities of prothrombinase at the capillary 
wall, we could use the earlier developed transport theory to 
estimate the prothrombin concentration at the catalytic 
0 1995 American Chemical Society 
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surface. Our data show unequivocally that the inhibition of 
prothrombinase by antithrombin is fully competitive with 
prothrombin. 
MATERIALS AND METHODS 
Materials. Glass capillaries with an inner diameter of 0.65 
mm and a length of 127 mm (volume of 42 pL) were 
obtained from Brand AG (Wertheim, Germany). 1,2- 
Dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC)' and 1,2- 
dioleoyl-sn-glycero-3-phosphatidylserine (DOPS) were pur- 
chased from Avanti Polar Lipids, Inc. (Alabaster, AL). 
S2238, chromogenic substrate for thrombin, was obtained 
from Chromogenix (Molndal, Sweden). Bovine serum 
albumin was from Sigma (St. Louis, MO). The 4th 
International Standard for Heparin (UFH) was a gift from 
the National Institute for Biological Standards and Control 
(Potters Bar, U.K.). Its potency was stated as 193 units mg-I. 
The molar concentration of the heparin with high affinity 
for antithrombin, as determined by stoichiometric titration 
with antithrombin (Schoen et al., 1990b), was 35 pmol g-'. 
Bovine factor Va, human prothrombin, human factor Xa, and 
human antithrombin were purified and quantified as de- 
scribed (Lindhout et al., 1982; Schoen et al., 1989). 
The Flow Reactor. The glass capillaries were cleaned and 
rendered hydrophilic as described (Billy et al., 1995). In 
order to deposit a phospholipid bilayer on the capillary wall, 
the glass capillary was filled and incubated for 20 min with 
a suspension of unilamellar phospholipid vesicles (25 mol 
% DOPS/75 mol % DOPC) in Tris buffer (50 mM Tris- 
HCl, 175 mM NaC1, pH 7.9). To remove nonbound 
phospholipid, the capillary was rinsed at a flow rate of 1.2 
mL min-' with Tris buffer containing 3 mM CaClz and 0.5 
mg mL-' bovine serum albumin. The phospholipid-coated 
capillary was connected to a syringe, and the flow was 
controlled by a syringe pump (Harvard Apparatus Co., South 
Natick, MA). An XYZ translation table (Isel, Eiterfelt, 
Germany) was used to collect samples from the tip of the 
flow reactor into disposable cuvettes (Sarstedt, Numbrecht, 
Germany). All procedures were performed at 37 "C. 
Inhibition of Phospholipid-Bound Prothrombinase. All 
perfusions were performed at 37 "C and pH 7.9 in Tris buffer 
containing 50 mM Tris-HC1, 175 mM NaCl, 3 mM CaC12, 
and 0.5 mg mL-' bovine serum albumin. Prothrombinase 
was assembled at the capillary wall by perfusion with a 
solution containing 1 pM factor Xa and 1 nM factor Va for 
10 min at a flow rate of 30 p L  min-I (wall shear rate 20 
s-I). Then the thrombin production was measured by 
perfusion with a mixture containing 1 nM factor Va and 
prothrombin. Samples of 60 p L  of effluent were collected, 
each 2 min, into cuvettes containing 500 p L  of Tris buffer 
containing 20 mM EDTA. The amounts of thrombin in the 
sample were measured spectrophotometrically after addition 
of 60 p L  of the chromogenic substrate S2238 (2.5 mM). The 
inhibition of prothrombinase was studied by perfusion with 
a mixture containing antithrombin or antithrombin-heparin, 
1 nM factor Va, and various concentrations of prothrombin. 
Data Analysis. In a previous study (Billy et al., 1995) 
we showed that the thrombin production J I I ~  (pmol min-') 
Billy et al. 
in a capillary flow reactor containing an amount E (pmol) 
of prothrombinase can adequately be described by Michae- 
lis-Menten kinetics in terms of kcat (3600 min-l), K, (3 nM), 
and the prothrombin concentration C, (nM) near the lipid 
membrane at the capillary wall: 
The concentration C, is lower than the concentration c b  in 
perfusion buffer at the inlet of the capillary due to the limited 
rate of mass transfer of protein from solution to the capillary 
wall: 
Co = Cb - JIIa/A ( 2 )  
with A the mass transfer coefficient (L min-I), which 
depends on the capillary dimensions, the fluid flow rate, the 
kinematic viscosity of the fluid, and the diffusion constant 
of the protein (Willems et al., 1993; Billy et al., 1995). For 
the experimental conditions used in this study a theoretical 
value of A = 10.8 p L  min-' can be calculated (Billy et al., 
1995). For high densities of prothrombinase on the capillary 
wall the depletion of prothrombin is nearly complete, i.e., 
C, x 0, and thrombin production becomes entirely transport 
rate limited J1la = ACb. Using this notion, we determined 
the value of the mass transfer from measurements of the 
thrombin production at high surface density of prothrombi- 
nase (0.75 fmol), which is attained after a 60 min perfusion 
with 2 pM factor Xa, 50 pM factor Va, and 50-200 nM 
prothrombin. This resulted in a value 9.8 k 0.25 p L  min-I 
(mean k SEM, n = 10) for the mass transfer coefficient A. 
Equations 1-2 can be used to predict the thrombin 
production for a given amount E of prothrombinase and a 
given prothrombin concentration Cb. Alternatively, one can 
estimate the amount of prothrombinase present in the 
capillary from the steady-state thrombin production: 
The applicability of eqs 2-3 for the assessment of the 
amount of prothrombinase is limited to low densities, Le., 
situations with a thrombin production below 90% of the 
transport limit. The calculation of C, near the transport limit 
involves large relative errors, because JldA approaches c b .  
Equations 2-3 were used to measure the decline of pro- 
thrombinase bound to the capillary by assessment of the 
steady-state rate of thrombin production before and after 
exposure to antithrombin-prothrombin mixtures. 
Analysis of competitive inhibition of prothrombinase in 
the flow reactor is complicated by the depletion of the 
substrate near the capillary wall. For purely competitive 
inhibition only the fraction of the enzyme not occupied by 
the substrate is susceptible to inhibition. According to eq 1 
the fraction of enzyme not occupied by substrate depends 
on the substrate concentration, C,, near the wall and is equal 
to K,l(C, + K,). The disappearance rate of the enzyme E 
thus is given by 
dldt E = -ki,,IEK,/(C0 + K,) (4) 
I Abbreviations: DOPS, 1,2-dioleoyl-sn-glycero-3-phosphatidylsenne; 
DOPC, 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine: S2238, H-D- 
phenylalanyl-L-pipecolyl-L-arginine-p-nitroanilide; UFH, unfractionated 
heparin: Tris, tris(hydroxymethy1) aminomethane, EDTA, ethylenedi- 
aminetetraacetic acid. 
with kinh the second-order rate constant of inhibition of the 
unprotected enzyme and I the concentration of the inhibitor. 
As consequence of the progressive inhibition of the enzyme, 
the concentration C,, however, is not constant but increases 
Competitive Inhibition of Prothrombinase 
in time, because a lower thrombin production results in a 
higher value of C, according to eq 2. Therefore, the term 
ki,hlK,/(C, + K,) is not constant, and the decay of enzyme 
is not exponential. Formal integration of eq 4 results in the 
expression 
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-ln(Ee/E,) = kinhZte[( l/te)h'eKm/(Co(r) + K,) dz] ( 5 )  
for the residual enzyme activity E, after exposure time re to 
the inhibitor. The term in square brackets represents the 
mean value of the protection factor, K,/(C, + K,), during 
the inhibition step. Evaluation of this term would require 
intermediate values of C,(t), which are difficult to obtain 
because inhibition measurements only provide values of E 
and C, at the start, t = 0, and the end, t = te, of the perfusion 
with inhibitor. It appears, however, that the approximation 
K,,,/([C,(O) + Co(t,)]/2 + K,) of the mean value of the 
protection factor provides sufficient accuracy (see below). 
Insertion of this approximation in eq 5 results in the following 
simple modification of the classical formula for competitive 
inhibition: 
-ln(E,/E,) = kinhZteKm/([Co(0) + Co(te)]/2 + K,) 
Rearrangement of this equation results in 
-ItJln(E,/E,) = l/(K,kinh)[C,(0) + C,(te)]/2 + l/ki,h 
(6)  
Data thus can be analyzed in a plot of -lte/ln(Ee/Eo) versus 
[C,(O) + C,(t,)]/2. The validity of the approximation of eq 
6 was assessed by numerical simulations of eq 4. 
For known values of the rate constants, A, k,,,, K,, and 
k,,h, and the prothrombinase density E, the value of C, can 
be calculated using eqs 1-2: 
C, = 0.5[Cb - K ,  - kCatE/A + 
J < ( c b  - K, - kC&/A)* f 4cbKm)1 (7) 
Equation 4, therefore, can be solved numerically for given 
values of the rate constants and a given prothrombinase 
density E, at the start of the exposure to the inhibitor. Such 
numerical simulations showed that the error in the parameters 
K,  and kinh caused by the approximation used in eq 6 
amounted to less than 4% of the estimated values. 
RESULTS 
Inhibition of Prothrombin Activation by Antithrombin. 
Our experimental approach requires the estimation of C,, 
the concentration of prothrombin near the capillary wall. This 
is only possible for thrombin productions below 90% of the 
transport limit. It was calculated using eqs 1-2 that this 
condition is satisfied for all values of the prothrombin 
concentrations in the perfusate if the amount of prothrom- 
binase bound to the capillary remains below 0.09 fmol. We 
choose to target at a prothrombinase content of 0.08 fmol. 
This amount of prothrombinase can be assembled by 
perfusion (30 pL min-') for IO min with mixture containing 
1 pM factor Xa and 1 nM factor Va. 
After this perfusion, the prothrombinase activity in the 
capillary was measured from the steady-state thrombin 
production upon perfusion with prothrombin (50 nM) and 
factor Va (1 nM) for 20 min. Figure 1 shows that the 
0.30 1 I 
O F  I 
0 20 40 60 80 
Time (min) 
FIGURE 1: Inhibition of prothrombinase activity by antithrombin. 
Fixed amounts of prothrombinase were assembled on the capillary 
wall in a perfusion with 1 pM factor Xa and 1 nM factor Va for 10 
min. Prothrombinase activity was measured upon perfusion with 
50 nM prothrombin and 1 nM factor Va. After 20 min the perfusion 
mixture was changed to a solution containing 2 pM antithrombin, 
50 nM prothrombin, and 1 nM factor Va, and the perfusion was 
continued for 6, 10, 16, 20, 30, and 40 min. Following this 
inhibition step, remaining prothrombinase activity was determined 
by a second perfusion with 50 nM prothrombin and 1 nM factor 
Va for 20 min. Volumetric flow of the perfusions was 30pL min-I 
(wall shear rate of 20 SKI). Experiments were performed at 37 "C 
and pH 7.9 in buffer containing 50 mM Tris-HC1, 175 mM NaCl, 
0.5 mg mL-' BSA, and 3 mM CaC12. 
thrombin production reached within 10 min a stable level 
of 0.27 f 0.001 pmol min-' (mean iz SD, n = 7). Thus a 
reproducible amount of 0.084 f 0.0004 fmol of prothrom- 
binase, calculated according to eqs 2-3, is assembled at the 
capillary wall. The measured thrombin formation is about 
50% of the transport limit, 0.49 pmol min-' at 50 nM 
prothrombin. Next, the prothrombinase was exposed to 
antithrombin for various times by continuation of the 
perfusion with a mixture containing antithrombin (2 pM), 
prothrombin (50 nM), and factor Va (1 nM). The thrombin 
concentration, measured at the outlet of the capillary, dropped 
to a low level, presumably because most of the thrombin 
generated is inactivated by antithrombin during the residence 
time of more than 1 min in the capillary. Finally, residual 
prothrombinase activity was measured during a second 
perfusion with prothrombin (50 nM) and factor Va (1 nM). 
The thrombin generation was restored to a new steady-state 
level of thrombin production lower than the initial rate of 
thrombin production. It is apparent that the residual pro- 
thrombinase activity decreases with increasing duration of 
the antithrombin perfusion. Residual thrombin production 
after 6 min exposure was 90% and decreased to 58% after 
40 min exposure. Control experiments showed that in 
absence of antithrombin the thrombin production remained 
stable during 50 min (residual production > 99% of the initial 
steady-state production). 
The thrombin production rates presented in Figure 1 permit 
the quantification of the amount of prothrombinase remaining 
in the capillary after inhibition using eqs 2-3. Figure 2 
shows a plot of the residual prothrombinase activity as 
function of the inhibition time. An exponential fit to these 
data results in an apparent first-order rate constant of 
prothrombinase inhibition kapp = 0.017 min-', which corre- 
sponds to a second-order rate constant of 0.008 x lo6 M-' 
min-I. In contrast, a fit of the model for competitive 
inhibition to these data, according to eqs 4 and 7, using a 
fixed value for K, = 3 nM (Billy et al., 1995), resulted in 
a value kinh = 0.085 x lo6 M-I min-' for the second-order 
rate constant of inhibition. This 10-fold higher value, which 
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FIGURE 2: Extent of prothrombinase inhibition by antithrombin as 
function of inhibition time. The residual amount of prothrombinase 
bound to the capillary was calculated using eqs 2-3 from the 
thrombin production shown in Figure 1 .  Also indicated is the best 
fitting curve, according to the competitive inhibition model (eq 4) 
with fixed value of K,,, = 3 nM. 
is in excellent agreement with the value 0.085 x lo6 M-' 
min-l found for inhibition by antithrombin in absence of 
prothrombin (Speijer et al., 1995), reflects the effective 
protection of prothrombinase by prothrombin: the prothrom- 
bin concentration C, at the capillary wall, calculated accord- 
ing eq 2, in these experiments varied during the antithrombin 
perfusion between 23, at the start, and 34 nM, at the end. 
This corresponds to an average fractional occupation, CJ 
(K, + C,), of the prothrombinase of about 90%, resulting 
in a 90% protection of the prothrombinase for inhibition by 
antithrombin in the model for competitive inhibition, cf. eq 
4. 
Analysis of Competitive Inhibition of Prothrombinase by 
Antithrombin. In order to obtain quantitative data on the 
effect of prothrombin on prothrombinase inhibition in the 
flow reactor, experiments as shown in Figure 1 were 
performed for several prothrombin concentrations (0-200 
nM). The inhibition step consisted of a perfusion during 10 
min with a mixture containing factor Va (1 nM), prothrom- 
bin, and antithrombin (0-4 pM). The initial and residual 
amount of prothrombinase bound to the capillary, E, and 
E,, were quantified by using eqs 2-3 from the initial and 
final steady-state level of thrombin production, respectively. 
These experiments unequivocally showed that the inhibition 
kinetics of prothrombinase depends on the prothrombin 
concentration present in the perfusion mixture. For 10 nM 
prothrombin, the apparent second-order rate constant of 
inhibition was 0.061 x lo6 M-] min-', while at 200 nM 
prothrombin the apparent second-order rate constant was 30- 
fold lower (0.002 x lo6 M-' min-' ). A fit with the model 
for competitive inhibition to these data with a fixed K, value 
of 3 nM resulted in a value 0.079 x lo6 M-I min-' for the 
true second-order inhibition constant kinh. 
The previous results indicate competition between anti- 
thrombin and prothrombin for the active site of the pro- 
thrombinase complex. In the analysis of these data with the 
competitive binding model, we, however, used the K, value 
as obtained from the kinetics of prothrombin conversion. In 
order to analyze the data with the model for competitive 
inhibition and to identify the K, value independently using 
eq 6, we performed additional experiments at low prothrom- 
bin concentrations (0-30 nM) and an antithrombin concen- 
tration of 4 p M  during the 10 min lasting inhibition perfusion. 
The results are presented in Figure 3 as the plot of -It,/ln- 
(E,/Eo) versus the average concentration C, at the capillary 
-5 0 5 10 
Prothrombin (nM) 
FIGURE 3: Competitive prothrombinase inhibition by antithrombin. 
The experimental protocol for the measurement of prothrombinase 
inhibition, as described in Figure 1, was executed for several 
prothrombin concentrations and an antithrombin concentration of 
4 ,uM during the 10 min inhibition step. Shown is a plot of -he/ 
ln(E,/E,) versus the mean prothrombin concentration, C0(0)/2 + 
C0(t,)/2, at the capillary wall during the perfusion with the 
prothrombin-antithrombin mixture. The straight line is the best 
fi t  of the model (eq 6) to these data with estimated values kinh = 
0.055 x lo6 M-I min-' and K, = 2.5 nM. 
wall, cf. eq 6. According to this equation, data should 
represent a straight line with a slope l/(Kmkinh) and an 
intercept at the vertical axis of l/kinh, with K, the Michaelis 
constant and kinh the true second-order rate constant of 
inhibition. The good agreement between data and the model 
of competitive inhibition in eq 6 is apparent. The best fitting 
straight line results in values K m  = 2.5 nM and kinh = 0.055 
x lo6 M-l min-I. A fit of eq 1 to the steady-state thrombin 
generation measured prior to the inhibition step as function 
of the prothrombin concentration resulted in a K, value of 
3.2 nM. This excellent agreement between these indepen- 
dently determined K, values corroborates the validity of the 
competitive inhibition model. 
We further addressed the question whether inhibition of 
prothrombinase by antithrombin-heparin complexes also is 
fully competitive. In perfusion experiments the inhibition 
step was performed with a mixture containing antithrombin 
(0.4 pM) and unfractionated heparin (0.05 p g  mL-l). The 
antithrombin concentration was chosen 10-fold lower than 
in the previous experiments in order to minimize the 
inhibitory effect of antithrombin alone. Yet, the concentra- 
tion of 0.4 p M  is sufficiently high to justify the assumption 
that all heparin is associated with antithrombin (Schoen et 
al., 1990b). The concentration of heparin-antithrombin 
complexes is 1.75 nM. The results, presented in Figure 4, 
show a good agreement between the data and the model of 
competitive inhibition. The best fitting straight line corre- 
sponds to the values K, = 2.0 nM and kinh = 128 x lo6 
M-l min-l. Thus, the heparin-dependent inhibition of 
prothrombinase in the presence of prothrombin can also be 
described by a simple competition model. 
DISCUSSION 
The present study demonstrates that the nearly complete 
protection by prothrombin of prothrombinase for inhibition 
by antithrombin and antithrombin-heparin, reported earlier 
(Schoen et al., 1991; Speijer et al., 1995), is completely 
explained by the competition of both proteins for the active 
site of factor Xa. This finding stresses the significance of 
the extremely high catalytic efficiency of prothrombinase 
Competitive Inhibition of Prothrombinase 
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it is calculated that the antithrombin concentration at the 
capillary wall is at most 31 nM (<1.5%) below the bulk 
concentration of 2-4 pM. For the antithrombin-heparin 
complexes (concentration 1.75 nM) the same reasoning 
would erroneously suggest a massive depletion. In the steady 
state, however, no net heparin consumption takes place at 
the capillary wall as heparin from the antithrombin- 
heparin-thrombin complexes is released and reassociates 
with antithrombin. Therefore, thrombin production only 
results in a small (<7% at 0.4 p M  antithrombin) depletion 
of antithrombin at the capillary wall. 
Limited protective effects of phospholipids and factor Va 
on the inhibition of factor Xa by antithrombin and anti- 
thrombin-heparin have been reported earlier (Marciniak, 
1973; Teitel, 1983; Ellis et al., 1986; Barrowcliffe et al., 
1987). A somewhat larger reduction of the inhibition rate, 
namely, 4-8-fold compared to factor Xa, was reported for 
factor Xa assembled in prothrombinase during thrombin 
generation (Lindhout et al., 1986; Schoen et al., 1989). 
These experiments were performed with prothrombinase 
assembled on small unilamellar vesicles in the presence of 
0.5- 1.5 p M  prothrombin. The limited protection observed 
in these earlier studies is compatible with competitive 
inhibition, because of the relatively high value of K, (0.1 - 
0.2pM) found for small vesicles (Rosing et al., 1980; Giesen 
et al., 1991). Also in clotting plasma the inhibition rate of 
prothrombinase is significantly lower than that of free factor 
Xa (Beguin et al., 1988). 
Interestingly, the inhibition rate found in the present study 
for prothrombinase not occupied by prothrombin is compa- 
rable to the inhibition rate reported for free factor Xa in the 
presence of Ca2+. For inhibition by antithrombin, we 
observed a true second-order rate constant of 0.06 x lo6 
M-l min-I, which is only 50% lower than the value, 0.12 x 
lo6 M-I min-l , reported for free factor Xa (Olson, 1992). 
The value k i n h  = 130 x lo6 M-' min-l for antithrombin- 
heparin (UFH) is even closer to the value k i n h  = 180 x lo6 
M-' min-' calculated by interpolation from the rate constants 
k i n h  = 260 x lo6 M-l min-I at 1.5 mM CaC12 and 120 x 
lo6 M-' min-l at 4 mM CaC12 found for free factor Xa 
(Schoen et al., 1992). 
Prothrombin activation is a more intricate process than 
most enzymatic reactions analyzed in studies on competitive 
inhibition. First, the extremely high catalytic efficiency (kcat/ 
K, = 2 x 1O1O M-l S - I )  of prothrombin activation by 
prothrombinase bound to the macroscopic lipid membrane 
(Billy et al., 1995) is considerably higher than the diffusion 
limit [about 2-3 x lo9 M-' s-l (Giesen et al., 1991)] for 
solution-mediated substrate supply. By comparison of the 
kinetics of prothrombin activation on small and large vesicles 
and on planar membranes in this earlier study, we demon- 
strated that the value of K, decreases with increasing 
membrane area surrounding the prothrombinase. It was 
concluded that the fluxes of prothrombin from solution to 
the membrane and on the membrane toward the prothrombin 
converting complex, both regulated by the resulting pro- 
thrombin concentration in solution near the membrane, 
govern the kinetics of prothrombin conversion. The mem- 
brane acts as a funnel that facilitates the collection of 
prothrombin that once bound to the membrane is efficiently 
delivered to the prothrombinase by lateral transport (Giesen 
et al., 1991). Secondly, processing of prothrombin by 
prothrombinase involves two successive proteolytic cleavages 
._ 
E 
f 0.04 
v 
0- 
-5 0 5 10 
Prothrombin (nM) 
FIGURE 4: Competitive prothrombinase inhibition by antithrombin- 
heparin complexes. Inhibition experiments were performed as 
described in the legend of Figure 3 with mixture containing 
antithrombin (0.4 pM) and heparin (0.05 mg L-I). This corresponds 
to a concentration of I = 1.75 nM of heparin-antithrombin 
complexes and 398 nM antithrombin. Shown is a plot of -Z?JIn- 
(Ee/&) versus the mean prothrombin concentration, C,(0)/2 -I- C,- 
(re)/2, at the capillary wall during the inhibition step. The straight 
line is the best fit of the model (eq 6) to these data with estimated 
values kinh = 128 x lo6 M-I min-' and K,,, = 2.0 nM. 
complex assembled on macroscopic phospholipid bilayers. 
The low value of the Michaelis constant, K, = 3 nM, on 
these surfaces, nearly two orders of magnitude lower than 
found for small unilamellar vesicles, results in highly 
effective protection by prothrombin of the prothrombinase 
complex for active site directed inhibitors like antithrombin. 
The simple formalism as presented in eqs 1-3 could be 
developed because prothrombinase assembly in the flow 
reactor is transport rate limited (Billy et al., 1995). This 
circumstance enabled us to simplify the description of mass 
transfer of prothrombin from solution to the wall of the flow 
reactor as given in eq 2 in terms of a mass transfer coefficient 
and a uniform (site independent) concentration C, at the 
capillary wall. By using this formalism, we could show that 
the kinetics of thrombin production conforms to simple 
Michaelis-Menten kinetics. In this paper we extended this 
formalism to enable the analysis of competitive inhibition, 
cf. eqs 4-7. Our experimental approach exploits the facility 
to assemble reproducible amounts of prothrombinase on the 
wall of the flow reactor by a perfusion with a mixture of 
factor Va and factor Xa that remains bound and stable even 
during perfusions lasting more than 50 min. Therefore, the 
rate of prothrombinase inactivation can be calculated from 
the amount of residual prothrombinase after exposure to a 
perfusion with antithrombin or antithrombin-heparin. 
A point of concern for the interpretation of our data could 
be the competition for antithrombin between locally produced 
thrombin and FXa assembled in the prothrombinase complex 
at the capillary wall. One prothrombinase complex produces 
about 3000 thrombin molecules per min, and the consump- 
tion of antithrombin by this thrombin potentially could result 
in depletion of antithrombin at the wall. Such depletion 
would result in a decreased inactivation rate of prothrom- 
binase with increasing thrombin production and therefore 
would present a trivial alternative explanation for the 
observed decreasing rate of inhibition with increasing pro- 
thrombin concentration near the catalytic surface. However, 
the maximal thrombin production in this study was below 
0.3 pmol min-I, and antithrombin consumption at the 
capillary wall is thus less than 0.3 pmol min-l. Using eq 2 
13704 Biochemistry, Vol. 34, No. 41, 1995 
(Rosing et al., 1986; Krishnaswamy et al., 1986). Despite 
the gross simplification associated with the application of 
the simple Michaelis-Menten model, several studies have 
shown a good agreement between model and measured 
activation kinetics both on vesicles (Nesheim et al., 1979; 
Rosing et al., 1980; Giesen et al., 1991) and on planar 
bilayers (Giesen et al., 1991; Willems et al., 1993; Billy et 
al., 1995). The present study extends this observation: 
identical values for K ,  were obtained from kinetics of 
prothrombin conversion and from the prothrombin dependent 
kinetics of prothrombinase inhibition. This confirms the 
notion that the Michaelis constant reflects the binding of 
prothrombin to factor Xa in the prothrombinase complex. 
Comparison of pentasaccharide and UFH revealed that the 
latter heparin on molecular basis is about 30-fold more 
effective as an inhibitor of prothrombinase (Speijer et al., 
1995). This suggests a role of heparin-prothrombinase 
interaction in the enhanced inhibition in addition to the 
pentasaccharide. Despite this conjectured interaction, our 
data show that inhibition of prothrombinase by heparin- 
antithrombin complexes is also fully competitive, with a 
similar value of the Michaelis constant, K ,  = 2 nM, 
estimated from the inhibition kinetics. 
The observation that inhibition of prothrombinase by 
antithrombin is fully competitive with prothrombin conver- 
sion is probably physiological relevant. With a value of the 
Michaelis constant K,,, = 3 nM nearly 700- 1000-fold below 
the plasma concentration, our observation indicates a com- 
plete protection of prothrombinase during the initial phase 
of activation of the coagulation cascade. 
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